Dr Pascal Duijf from QUT's School of Biomedical Sciences and IHBI (Institute of Health and Biomedical Innovation) said the study analyzed chromosome arm abnormalities in more than 23,000 human tumors and 1000 cancer cell lines.
"Our analyses provided hitherto unknown insights into the evolution of tumors and open up three exciting new areas of study, including new potential personalized treatments for 17 cancer types," Dr Duijf said.
"Nearly all cells in our bodies have 46 chromosomes, made up of DNA and proteins, that contain genetic information and instructions for cell functions.
"Most chromosomes have two chromosome arms. If cancer cells gain or lose arms, it can equip them with cancerous features, such as the ability to spread through the body.
"Our most unexpected finding was that chromosome arm gains and losses predict drug response much better than well-established genetic abnormalities, such as mutations.
"We used artificial intelligence to identify 31 chromosome arm gains or losses that profoundly change the response of cancer cells to 56 different chemotherapeutic drugs."
Dr Duijf said tumor cells usually initially gain chromosome arms and lose multiple arms later during development.
Blood cancers, on the other hand, acquire only few chromosome arm abnormalities and show more gains than losses.
"We also applied advanced statistical methods to determine probable orders in which chromosome arms are gained and lost during the development of breast cancer," he said.
"We found that chromosome arm gains and losses could also predict patient survival outcome in 58 per cent of nearly 7000 patients with 19 types of cancer.
"Unexpectedly, although chromosome arm gains and losses are abnormal, for 1 in 4 patients they predict better survival outcome."
Shukla et al. (2019) Chromosome arm aneuploidies shape tumour evolution and drug response. Nature Communications. DOI: https://doi.org/10.1038/s41467-020-14286-0
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.